Literature DB >> 16001409

Preserved cardiac sympathetic nerve accounts for normal cardiac uptake of MIBG in PARK2.

Satoshi Orimo1, Takeshi Amino, Masayuki Yokochi, Tohru Kojo, Toshiki Uchihara, Atsushi Takahashi, Koichi Wakabayashi, Hitoshi Takahashi, Nobutaka Hattori, Yoshikuni Mizuno.   

Abstract

We performed [123I] MIBG myocardial scintigraphy in two of three patients with PARK2 from unrelated families and examined the heart tissues from the three patients immunohistochemically using an antibody against tyrosine hydroxylase (TH) to see whether cardiac sympathetic nerve is involved. Cardiac uptake of MIBG was normal except for a slight decrease in the late phase in one of the patients. Postmortem examination revealed that TH-immunoreactive nerve fibers in the epicardium were well preserved in all three patients. The present study confirmed that cardiac sympathetic nerve is well preserved in PARK2 with a homozygous exon deletion, which accounts for normal cardiac uptake of MIBG. Moreover, normal cardiac uptake of MIBG might be of potential diagnostic value to indicate the absence of Lewy body pathology, even in patients with levodopa-responsive Parkinsonism, as in PARK2. Copyright (c) 2005 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16001409     DOI: 10.1002/mds.20594

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  25 in total

1.  Cardiac 123I-MIBG scintigraphy: A window into the brain in Parkinsonism?

Authors:  Lamotte Guillaume; Agostini Denis
Journal:  J Nucl Cardiol       Date:  2015-12-07       Impact factor: 5.952

2.  Myocardial 123I-metaiodobenzylguanidine scintigraphy in patients with homozygous and heterozygous parkin mutations.

Authors:  Anna De Rosa; Teresa Pellegrino; Sabina Pappatà; Maria Teresa Pellecchia; Silvio Peluso; Francesco Saccà; Paolo Barone; Alberto Cuocolo; Giuseppe De Michele
Journal:  J Nucl Cardiol       Date:  2015-12-01       Impact factor: 5.952

3.  A Peruvian family with a novel PARK2 mutation: Clinical and pathological characteristics.

Authors:  Mario R Cornejo-Olivas; Luis Torres; Ignacio F Mata; Pilar Mazzetti; Diana Rivas; Carlos Cosentino; Miguel Inca-Martinez; Juan M Cuba; Cyrus P Zabetian; James B Leverenz
Journal:  Parkinsonism Relat Disord       Date:  2015-01-15       Impact factor: 4.891

4.  Neuroscience and heart-brain medicine: the year in review.

Authors:  David S Goldstein
Journal:  Cleve Clin J Med       Date:  2010-07       Impact factor: 2.321

Review 5.  Modeling and imaging cardiac sympathetic neurodegeneration in Parkinson's disease.

Authors:  Valerie Joers; Marina E Emborg
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-03-20

Review 6.  Twenty years since the discovery of the parkin gene.

Authors:  Nobutaka Hattori; Yoshikuni Mizuno
Journal:  J Neural Transm (Vienna)       Date:  2017-06-15       Impact factor: 3.575

7.  Diagnosis of dementia with Lewy bodies: can 123I-IMP and 123I-MIBG scintigraphy yield new core features?

Authors:  Fumi Sakamoto; Shinya Shiraishi; Noriko Tsuda; Mamoru Hashimoto; Seiji Tomiguchi; Manabu Ikeda; Yasuyuki Yamashita
Journal:  Br J Radiol       Date:  2016-11-29       Impact factor: 3.039

Review 8.  Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature.

Authors:  Susanne A Schneider; Roy N Alcalay
Journal:  Mov Disord       Date:  2017-11       Impact factor: 10.338

9.  Evaluation of gastric emptying in familial and sporadic Parkinson disease.

Authors:  Anna Krygowska-Wajs; William P Cheshire; Zbigniew K Wszolek; Alicja Hubalewska-Dydejczyk; Barbara Jasinska-Myga; Matthew J Farrer; Marek Moskala; Anna Sowa-Staszczak
Journal:  Parkinsonism Relat Disord       Date:  2009-05-17       Impact factor: 4.891

Review 10.  Neurogenic orthostatic hypotension: a pathophysiological approach.

Authors:  David S Goldstein; Yehonatan Sharabi
Journal:  Circulation       Date:  2009-01-06       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.